Last reviewed · How we verify
Other ART regimens
Other ART regimens refer to alternative antiretroviral therapy combinations used to treat HIV infection when standard first-line regimens are not suitable or have failed.
Other ART regimens refer to alternative antiretroviral therapy combinations used to treat HIV infection when standard first-line regimens are not suitable or have failed. Used for HIV-1 infection in treatment-experienced patients, HIV-1 infection with antiretroviral resistance, HIV-1 infection in patients with contraindications to standard first-line regimens.
At a glance
| Generic name | Other ART regimens |
|---|---|
| Sponsor | Juan A. Arnaiz |
| Drug class | Antiretroviral therapy combination regimen |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
ART regimens typically combine multiple antiretroviral drugs from different classes (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, entry inhibitors) to suppress HIV replication through complementary mechanisms. Alternative regimens are deployed in treatment-experienced patients, those with drug resistance, or those with contraindications to standard therapies.
Approved indications
- HIV-1 infection in treatment-experienced patients
- HIV-1 infection with antiretroviral resistance
- HIV-1 infection in patients with contraindications to standard first-line regimens
Common side effects
- Nausea
- Diarrhea
- Headache
- Lipodystrophy
- Hepatotoxicity
- Peripheral neuropathy
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- Immediate ART in Subjects With Opportunistic Diseases (NA)
- Incidence of HANA Conditions in HIV-infected Individuals
- Reducing Systemic Inflammation in People on Antiretroviral Therapy (PHASE2)
- Safety of Antimalarials in the FIRst trimEster (PHASE3)
- Early ART to Limit Infection and Establishment of Reservoir (PHASE2)
- Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine (PHASE3)
- A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Other ART regimens CI brief — competitive landscape report
- Other ART regimens updates RSS · CI watch RSS
- Juan A. Arnaiz portfolio CI